| EBDCT | Cockayne-Touraine type of epidermolysis bullosa dystrophica |
|---|---|
| ECL | emitter-coupled logic; enterochromaffin-like [type]; euglobin clot lysis |
| HIB | heart infusion broth; hemolytic immune body; Hemophilus influenzae type B [vaccine] |
| HITB, HiTB | Hemophilus influenzae type B |
| HIV1 | human immunodeficiency virus type 1 |
| type I hyperlipoproteinaemia | <biochemistry> An rare inherited disorder where there is a deficiency of an enzyme (lipoprotein lipase) which breaks down fat molecules, causing the accumulation of fats or lipoproteins in the blood. Symptoms in infancy include abdominal pain (appears as if its colic), failure to thrive and skin lesions (xanthomas). Origin: Gr. Haima = blood (27 Sep 1997) |
|---|---|
| type II acrocephalosyndactyly | type II acrocephalosyndactyly |
| type II cells | Cuboidal cell's connected with the squamous pulmonary alveolar cell's and having in their cytoplasm lamellated bodies (cytosomes) that represent the source of the surfactant that coats the alveoli. Synonym: granular pneumonocytes, type II cells. (05 Mar 2000) |
| type II collagen | Collagen unique to cartilage, nucleus pulposis, notochord, and vitreous body; it forms as thin highly glycosylated fibrils. (05 Mar 2000) |
| type II diabetes | <disease> An often mild form of diabetes mellitus of gradual onset, usually in obese individuals over age 35; absolute plasma insulin levels are normal to high, but relatively low in relation to plasma glucose levels; ketoacidosis is rare, but hyperosmolar coma can occur; responds well to dietary regulation and/or oral hypoglycaemic agents, but diabetic complications and degenerative changes can develop. (05 Mar 2000) |
| type II dip | Late deceleration of the foetal heart rate, 30 seconds or more after the height of uterine contraction, as displayed on a foetal monitor graph. (05 Mar 2000) |
| type II error | The statistical error (said to be of the second kind or beta error) made in testing an hypothesis when it is concluded that a treatment or intervention is not effective when it really is. Sometimes referred to as a false negative. (12 Dec 1998) |
| type II familial hyperlipoproteinaemia | Hyperlipoproteinaemia characterised by increased plasma levels of beta-lipoproteins, cholesterol, and phospholipids, but normal triglycerides; heterozygotes have mild lipid changes and are susceptible to atherosclerosis in middle age, but homozygotes have severe changes often with generalised xanthomatosis and xanthelasma, and frank clinical atherosclerosis as young adults. The primary defect is a deficiency of apoprotein of VLDL, and the disorder is divided into two classes: 1) type IIA, which has elevated LDL due to a deficiency of the receptor or a modified apolipoprotein B-100; 2) type IIB, which has elevated LDL and triglycerides; autosomal dominant inheritance. Synonym: familial hyperbetalipoproteinaemia, familial hypercholesteraemic xanthomatosis, familial hypercholesterolaemia. (05 Mar 2000) |
| type II hyperlipoproteinaemia | <biochemistry> A relatively rare (7 out of 1,000) genetic disease in which there is elevation in the blood triglycerides, cholesterol and low density lipoprotein (LDL). Also called type II hyperlipoproteinaemia, familial hyperlipoproteinaemia or familial hypercholesterolaemia. Origin: Gr. Haima = blood (27 Sep 1997) |
| type II interferon | <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease. Pharmacological action: antineoplastic agent, antiviral agents. Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced) (12 Dec 1998) |
| type II mortality | <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy. (05 Dec 1998) |
| type II mucopolysaccharidosis | <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance. Synonym: type II mucopolysaccharidosis. (05 Mar 2000) |
| type I interferon | <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta). Pharmacological action: antineoplastic agent, antiviral agents. (12 Dec 1998) |
| type I mortality | <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy. (05 Dec 1998) |
| type IS mucopolysaccharidosis | <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage. Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome. (09 Oct 1997) |